BioCentury
ARTICLE | Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

August 6, 2019 11:44 PM UTC

Alnylam's Onpattro bests consensus
Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32 million, and is 45% higher than Onpattro's 1Q19 sales of $26.3 million. Alnylam launched Onpattro, the world's first approved RNAi therapeutic, in August 2018 (see "Agreement to Differ").

First peek at sales of Sage's antidepressant
Sage Therapeutics Inc. (NASDAQ:SAGE) believes sales of newly launched postpartum depression drug Zulresso brexanolone will gain momentum beginning in 4Q19 as more sites become treatment-ready. The company said that following the drug's official launch in the last week of 2Q19, quarterly sales amounted to $519,000, all from channel stocking. On a conference call Tuesday, CBO Michael Cloonan said that as of Aug. 1, there are more than 100 REMS-certified Zulresso care sites in the U.S., and plans representing more than 65% of covered lives have committed to provide "favorable" coverage of the drug...